In autumn, CHIPSCREEN BIOSCIENCES HDACi ( histone deacetylase inhibitor ) summit was solemnly held in Hangzhou.

HDACi ( histone deacetylase inhibitor ) is an anti-cancer drug with great development prospect in the future as an anti-tumor drug of epigenetic regulation. Especially in the field of blood lymphoma and solid tumors, it has been widely concerned by scholars at home and abroad. Epidaza? ( Chidamide ), originally created by CHIPSCREEN BIOSCIENCES, is the fastest growing oral subtype selective HDACi in the world. Since October 12, 2014, Epidaza?'s launch conferences have been successfully held in Beijing, Shanghai and Chengdu respectively. On December 23 of the same year, CFDA approved its first indication, " relapsed and refractory peripheral T-cell lymphoma (PTCL)". On February 16, 2015, Epidaza?'s first prescription was born. At present, in addition to the clinical application of PTCL indications that have been approved, several new indications have been developed at home and abroad in the area of blood lymphoma and solid tumors. The purpose of this conference is to share the latest clinical application and research progress of new drugs in HDACi class at home and abroad, exchange use experience of clinical practical drug and explore and initiate better solutions.